We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Durable Stable Disease by Atezolizumab/Bevacizumab Can Provide Long-term Survival of Patients With Hepatocellular Carcinoma Lung Metastases.
- Authors
TOSHIHIKO MOTOHARA; KENSUKE YAMAMURA; HIDEAKI MIYAMOTO; SHIGENORI UENO; HIROSHI TAKENO; YASUNORI NAGAYAMA; ERI ODA; RYUICHI KARASHIMA; NOBUYUKI OZAKI; TATSUNORI MIYATA; KOSUKE MIMA; HIROHISA OKABE; TAKATOSHI ISIKO; TORU BEPPU
- Abstract
Background: Multiple bilateral lung metastases secondary to hepatocellular carcinoma (HCC) are mainly treated with molecular therapy. Atezolizumab plus bevacizumab can provide excellent long-term survival for patients with a good response. Case Report: A 67-year-old woman underwent right hepatectomy for a primary solitary HCC, 11 cm in diameter, after portal embolization. After 2 years, she developed bilateral lung metastases with >100 nodules, <1 cm in size. She had no viral hepatitis or liver cirrhosis, and the Child–Pugh Grade was A (5 points). Lenvatinib (12 mg daily) was administered as a first-line treatment and continued for 18 months. The best response was stable disease (SD). Subsequently, intravenous atezolizumab (1,200 mg) plus bevacizumab (15 mg/kg) was administered once every three weeks. The best response was SD, which continued for 26 months. After that, cabozantinib treatment was initiated and discontinued after one cycle. Subsequently, dual immune checkpoint inhibitor treatment (durvalumab + tremelimumab) was administered. She has had multiple, but lung-only, metastases over four years. She has been well as an outpatient with the Child–Pugh Grade of A and a performance status of 0. Conclusion: Even if atezolizumab plus bevacizumab does not induce a good response, a durable SD could prolong survival in patients with metastatic HCC while maintaining liver function and a good quality-of-life.
- Subjects
HEPATOCELLULAR carcinoma; ATEZOLIZUMAB; BEVACIZUMAB; IMMUNE checkpoint inhibitors; LIVER function tests
- Publication
In Vivo, 2023, Vol 37, Issue 5, p2268
- ISSN
0258-851X
- Publication type
Article
- DOI
10.21873/invivo.13329